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Introduction
Acromegaly is an acquired disorder 
caused by excessive production of GH and 
IGF-1 and characterized by somatic 
disfiguration and systemic manifestations.
1
 
It is due to monoclonal growth hormone 
producing pituitary adenoma in 90% of 
cases. Acromegaly is rare, with an incidence 
of three cases per million persons per year.
2
  
Due to its insidious onset and slow 
progression the diagnosis of acromegaly 
typically is delayed 4-10 years after 
symptom onset (mean age at diagnosis 40 
years).
1
  
Acromegaly affects men and women 
equally.
1
 Impaired glucose tolerance and 
diabetes mellitus (DM) are common in 
patients with acromegaly, with a prevalence 
of 36% and 30%, respectively.
2
 Diabetic 
ketoacidosis (DKA) is a rare complication of 
acromegaly with only a few cases reported 
in the English medical literature.
3-15
 Factors 
that promote ketoacidosis in acromegalic 
patients include infection, surgical 
procedures, cessation of octreotide therapy, 
and excessive ingestion of sugar-containing 
soft drinks.
7
  
We present a case of a patient with no 
past medical history of DM who presented 
to the hospital for DKA and was found to 
have acromegaly. 
 
Case Report 
A 41-year-old Hispanic female presented 
with a three-month history of weakness. She 
also complained of a seven-day worsening 
of polydipsia and polyuria. Her prior 
medical history was significant for 
hypertension and hyperlipidemia. Her 
family history was noteworthy for type 2 
DM in her mother. The patient noticed an 
increase in the size of her hands and feet for 
approximately 12 years, with an increase in 
shoe size from 7.5 to 9. Menstrual periods 
had been absent for approximately six years. 
The physical examination was 
remarkable for a body mass index of 39 
kg/m
2
, blood pressure of 138/80 mmHg, 
heart rate of 98 beats/min, coarse facial 
features, and enlarged hands. Initial 
laboratory studies revealed a glucose of 359 
mg/dl, bicarbonate of 8.4 mmol/L, ketones 
present in blood and urine, and an anion gap 
of 24. Arterial blood gas revealed pH at 7.27 
with a pCO2 of 18 mmHg. Glycosylated 
hemoglobin (HbA1c) was 11.7 percent. 
There was neither laboratory nor physical 
evidence of infection, ischemia, or illicit 
drug use. 
A random growth hormone (GH) level 
was elevated at 98.2 ng/ml (0-6) and insulin-
like growth factor-1 (IGF-1) was elevated at 
398 ng/ml (101-267), consistent with 
acromegaly. Other laboratory test results are 
included in Table 1.  
Magnetic resonance imaging of the 
pituitary sella showed a mass arising from 
the pituitary that measured 2.1 x 1.8 cm, 
with bilateral cavernous sinus invasion and 
mass effect on the optic chiasm (Figure 1). 
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Table 1. Other laboratory values obtained on patient. 
Laboratory Test Value Normal range 
Thyroid-stimulating hormone (TSH) 0.32 μIU/ml 0.34 - 4.82 
Free thyroxine 1.4 ng/dl 0.9 - 1.8 
Morning adrenocorticotropic hormone 37.6 pg/ml 7.2 - 63.3 
Morning cortisol 18.9 mcg/dl 4.3 - 22.4 
Luteinizing hormone 0.2 mIU/ml 1.5 - 9.3 
Follicle-stimulating hormone 2.7 mIU/ml 1.4 - 18.1 
Prolactin 30 ng/ml 4.8 - 23.3 
 
 
 
Figure 1. The pituitary sella showed a mass 
arising from the pituitary.  
 
Intravenous fluids and insulin were 
administered for treatment of DKA. The 
metabolic acidosis resolved within 24 hours, 
and the patient was transitioned to 
subcutaneous insulin prior to uneventful 
transnasal sphenoidal resection of the mass.  
Pathologic examination was consistent 
with a pituitary adenoma (Figure 2) with 
immunohistochemical stains strongly 
positive for synaptophysin and prolactin 
(Figure 3) with focal positivity for GH 
(Figure 4). A lesser degree of diffuse 
positivity was noted for follicle stimulating 
hormone (Figure 5). This plurihormonal 
immunohistochemical staining pattern 
(especially predominating positive staining 
for prolactin with only focal positive 
staining for GH) is well-described in some 
patients with pituitary adenoma and clinical 
acromegaly, as in this patient.
16 
 
 
Figure 2. Pathologic examination was 
consistent with a pituitary adenoma. 
 
 
Figure 3. Immunostaining was positive for 
prolactin and synaptophysin. 
 
 
Figure 4. Immunostaining was positive for 
growth hormone. 
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Figure 5. Immunostaining was positive for 
follicle stimulating hormone. 
 
The patient was discharged on 
subcutaneous insulin, metformin, and 
lanreotide 60 mg intramuscularly monthly.  
At the two-month follow-up, the HbA1c 
level was 6.3% with a persistent elevation in 
the IGF-1 level at 907 ng/ml (68 - 225) and 
prolactin level at 50 ng/ml (4.8 - 23.3). 
Repeat MRI showed no evidence of residual 
or recurrent neoplasm. The patient was 
initiated on cabergoline 0.5 mg orally two 
times weekly for the hyperprolactinemia and 
lanreotide depot was increased to 90 mg 
intramuscularly monthly. At three months, 
the prolactin level had decreased to 3.2 
ng/ml (4.8 - 23.3) and the IGF-1 level had 
decreased to 620 ng/ml (68 - 225). The 
lanreotide depot dose was titrated upward to 
achieve a normal IGF-1 level. A repeat 
HbA1c was 6.0% and insulin was 
discontinued. 
 
Discussion 
The mechanism of DKA in acromegaly 
is thought to be a GH and IGF-1 mediated 
insulin resistance in the liver and peripheral 
tissues leading to increased endogenous 
glucose production, reduced peripheral 
glucose uptake, and consequently hyper-
glycemia and β-cell glucotoxicity with 
reduced insulin production.
14
 During fasting 
and other catabolic states, GH predom-
inantly stimulates lipolysis and the release 
and oxidation of free fatty acids. In addition, 
possible direct stimulation of hepatic keto-
genesis may explain diabetic ketoacidosis in 
some patients with acromegaly.
17
 Glucagon, 
a counter regulatory hormone important in 
the pathogenesis of DKA, may be elevated 
in patients with acromegaly.
14
  
The treatment of DM and the prevention 
of DKA need to be directed at decreasing 
GH/IGF-1 levels, either surgically or 
pharmacologically. Endocrine remission 
occurs in 50% of GH-secreting macro-
adenomas after surgery.
18
 Patients with 
acromegaly and DKA showed resolution of 
the DKA with standard medical therapy and 
reduced insulin requirements and oral 
hypoglycemic medications after trans-
sphenoidal surgery in previous case 
reports.
3-15
 These patients required insulin 
for 1-20 weeks post trans-sphenoidal 
surgery.
 
Our patient improved with the standard 
therapy for DKA with IV and subcutaneous 
insulin, IV fluids, and electrolyte 
replacement. Subcutaneous insulin was 
stopped three months after surgery. Our 
patient had a plurihormonal adenoma 
producing both GH and prolactin. Caber-
goline normalized her prolactin levels within 
three months. The elevation in her IGF-1 
level required escalation of the lanreotide 
depot dose. The clinical course of our 
patient was comparable to many cases 
previously reported with DKA and 
acromegaly that underwent trans-sphenoidal 
pituitary adenoma resection.
3-15 
 
Conclusion 
The definitive treatment of acromegaly 
is an important part of glycemic control in 
acromegalic patients presenting with DKA. 
There is need for further studies to evaluate 
the effect of somatostatin analogues and 
somatotroph tumor resection in the 
prevention of DKA in the long term. 
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